Taken together, these results support abnormally high CD4+ CD26− phenotype, demonstrate variability in the CD7 profile, and reveal significant differences in level of TNFR2 expression in SS patients compared to controls both with high expression on the tumor cells themselves and on the associated tumor-associated Tregs. The gene discussed is CD4; the disease is neoplasm.